HZNP News and Press, Horizon Therapeutics Public Limited Company From 03/01/22

My portfolio, built specifically for my retirement ~20+ years from now, experiences some major shifts as I play for upside in oil and former market darlings. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helpi...

Horizon Therapeutics PLC (HZNP) Q4 2021 Results Conference Call March 01, 2022 08:00 AM ET Company Participants Tina Ventura - SVP, IRO Tim Walbert - Chairman, President, CEO Elizabeth Thompson - EVP, Research & Development Paul Hoelscher - EVP, CFO Conference Call Participants Akash Tewa...

Shares of Horizon Therapeutics (NASDAQ:HZNP) are trading 4% higher in the premarket session after its Q4 2021 results beat on the top and bottom lines and it issued 2022 guidance. Net income in the quarter dropped ~9% to $173.2M compared to the prior-year period. Diluted EPS fell to...

Horizon Therapeutics press release (NASDAQ:HZNP): Q4 Non-GAAP EPS of $1.41 beats by $0.06. Revenue of $1.01B (+35.5% Y/Y) beats by $14.1M. Fourth-quarter 2021 adjusted EBITDA was $416.0 million and includes $36.2 million of upfront and milestone payments primarily related to the collaboration...

Fourth-Quarter 2021 Results: -- Net Sales of $1.01 Billion Increased 36% -- -- GAAP Net Income of $173.2 Million; Adjusted EBITDA of $416.0 Million -- -- TEPEZZA ® (teprotumumab-trbw) Net Sales of $589.6 Million Increased 72% -- -- KRYSTEXXA ...

PBE is neither suitable for income seekers, nor for long term investors. Despite being a Genomic revolution fund, it lacks focus, and invested heavily on large cap diverse biotechnology companies. Better biotechnology ETFs of similar nature are available in the market. For f...

Horizon Therapeutics (NASDAQ:HZNP) is scheduled to announce Q4 earnings results on Tuesday, Mar. 1, before market open. The consensus EPS estimate is $1.35 (+5.5% Y/Y) and the consensus revenue estimate is $995.9M (+33.6% Y/Y). Over the last 2 years, HZNP has beaten EPS estimates 88% of the t...

ADT,AGEN,AKBA,ALBO,AMRN,AMRS,AXSM,AZO,OTCPK:BAYZF,BIDU,BLDR,BMO,BNS,BSY,CCCS,CHS,CMRX,CRON,DPZ,EHTH,EPZM,EVRI,FOUR,OTCQX:GTBIF,HGV,HOV,HRL,HTA,HZNP,IGT,IQ,ITCI,KSS,KTB,LILM,MANU,MCRB,MLCO,NFE,OTCQB:NLST,NUWE,OKE,PIRS,PLTK,PRGO,QTRX,REGI,RYTM,SE,SJM,TGT,TGTX,TLS,TWNK,UWMC,VFF,VRTV,WEN,WKHS,XXI...

-- The new program and website are designed to create conversations that will lead to new resources to support diversity, equity, inclusion and allyship within the rare disease community -- -- #RAREis webcast conversation with The Akari Foundation, Amigos Múltiplos, Child...

-- Teprotumumab is marketed under the brand name TEPEZZA ® in the United States -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical trial (OPTIC-J) in Japan evaluating teprotumumab for the...